Emil D.  Kakkis net worth and biography

Emil Kakkis Biography and Net Worth

Dr. Kakkis is Chief Executive Officer, President and a Director of Ultragenyx. He founded Ultragenyx in 2010 to create a company that is uniquely built around a deep and meaningful engagement with patients and their caregivers to fully understand their needs. This includes designing a novel development model that fundamentally changed the established paradigms in clinical protocols, endpoints and analyses, as well as challenging traditional beliefs around commercialization and access to therapies for patients with rare and ultra-rare genetic diseases.

Dr. Kakkis began at the Harbor-UCLA Medical center where he was developing an enzyme replacement therapy for the rare disorder MPS I. He joined Biomarin in 1998 where he guided the development and approval of three treatments for rare diseases (MPS I, MPS VI and PKU) and contributed to the development of approved or development stage products for four other rare diseases (CLN2, MPSIVA, PKU, achondroplasia). He has worked to advance the cause of rare disease treatment through advocacy on policy issues by founding and supporting the EveryLife Foundation for Rare Diseases, a non-profit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies, regulatory policy and law.

Dr. Kakkis received a Lifetime Achievement Award from the National MPS Society, the Roscoe O. Brady Award for Innovation and Accomplishment from the WORLDSymposium, and BIO’s Henri Termeer Visionary Leadership award for this transformative work in rare diseases.

Dr. Kakkis serves on the Board of Odylia Therapeutics and the EveryLife Foundation.

Dr. Kakkis graduated from Pomona College, magna cum laude, and received the Vaile prize for his biology research. He received combined M.D. and Ph.D. degrees from the UCLA Medical Scientist Program and received the Bogen Prize for his research upon graduation. He completed a pediatrics residency and a Medical Genetics Training Fellowship at Harbor-UCLA Medical Center, where he was an assistant professor of pediatrics and initiated the enzyme therapy program for MPS I. Dr. Kakkis was board certified in pediatrics and medical genetics.

What is Emil D. Kakkis' net worth?

The estimated net worth of Emil D. Kakkis is at least $27.82 million as of October 19th, 2023. Dr. Kakkis owns 599,743 shares of Ultragenyx Pharmaceutical stock worth more than $27,816,080 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Kakkis may own. Additionally, Dr. Kakkis receives a salary of $1,370,000.00 as CEO at Ultragenyx Pharmaceutical. Learn More about Emil D. Kakkis' net worth.

How old is Emil D. Kakkis?

Dr. Kakkis is currently 64 years old. There are 7 older executives and no younger executives at Ultragenyx Pharmaceutical. Learn More on Emil D. Kakkis' age.

What is Emil D. Kakkis' salary?

As the CEO of Ultragenyx Pharmaceutical Inc., Dr. Kakkis earns $1,370,000.00 per year. Learn More on Emil D. Kakkis' salary.

How do I contact Emil D. Kakkis?

The corporate mailing address for Dr. Kakkis and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Emil D. Kakkis' contact information.

Has Emil D. Kakkis been buying or selling shares of Ultragenyx Pharmaceutical?

Emil D. Kakkis has not been actively trading shares of Ultragenyx Pharmaceutical during the last ninety days. Learn More on Emil D. Kakkis' trading history.

Who are Ultragenyx Pharmaceutical's active insiders?

Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.

Are insiders buying or selling shares of Ultragenyx Pharmaceutical?

During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 137,603 shares worth more than $5,319,366.32. The most recent insider tranaction occured on March, 11th when EVP Thomas Richard Kassberg sold 11,509 shares worth more than $574,644.37. Insiders at Ultragenyx Pharmaceutical own 6.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.

Information on this page was last updated on 3/11/2024.

Emil D. Kakkis Insider Trading History at Ultragenyx Pharmaceutical

See Full Table

Emil D. Kakkis Buying and Selling Activity at Ultragenyx Pharmaceutical

This chart shows Emil D. Kakkis's buying and selling at Ultragenyx Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $46.38
Low: $46.28
High: $47.08

50 Day Range

MA: $47.29
Low: $43.02
High: $53.69

2 Week Range

Now: $46.38
Low: $31.52
High: $54.98

Volume

32,305 shs

Average Volume

755,563 shs

Market Capitalization

$3.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66